Literature DB >> 3051700

Models for the analysis of radon-exposed populations.

J H Lubin1.   

Abstract

Radon-222 is a radioactive decay product of radium-226 and uranium-238, which are found throughout the crust of the earth. Studies of underground miners clearly show that exposure to radon and its decay products increases the risk of developing lung cancer. Data on standardized mortality ratios from eight cohort studies indicate that the radon-lung cancer relationship is statistically homogeneous, even though cohorts are from different types of mines and from different countries. Regression methods for cohort data based on a Poisson probability model permit a thorough consideration of risk patterns. In this report, we review these methods, wherein the disease rate in each cell of a multi-way table is modeled as a function of the cross-classifying variables. The National Academy of Sciences' Committee on the Biological Effects of Ionizing Radiation uses the Poisson regression approach to develop a model for age-specific lung cancer risk which depends on cumulative exposure, age at risk, and time since exposure. This model is reviewed and its implications discussed. The most important determinant of lung cancer is cigarette smoking. This paper discusses relative risk models for analysis of joint exposure to radon and tobacco products. The review of available studies suggests that the joint relationship of radon and smoking with lung cancer is consistent with a multiplicative model, but a submultiplicative relationship is most likely. An additive model is rejected.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3051700      PMCID: PMC2590446     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  32 in total

1.  Lung cancer in man in relation to different time distribution of radiation exposure.

Authors:  E Kunz; J Sevc; V Placek; J Horácek
Journal:  Health Phys       Date:  1979-06       Impact factor: 1.316

2.  The age distribution of human cancer for carcinogenic exposures of varying intensity.

Authors:  A S Whittemore
Journal:  Am J Epidemiol       Date:  1977-11       Impact factor: 4.897

3.  Relative risk models for assessing the joint effects of multiple factors.

Authors:  J H Lubin; W Gaffey
Journal:  Am J Ind Med       Date:  1988       Impact factor: 2.214

4.  Methods for testing interactions, with applications to occupational exposures, smoking, and lung cancer.

Authors:  D C Thomas; A S Whittemore
Journal:  Am J Ind Med       Date:  1988       Impact factor: 2.214

5.  Uranium mining and cigarette smoking effects on man.

Authors:  V E Archer; J K Wagoner; F E Lundin
Journal:  J Occup Med       Date:  1973-03

6.  Mortality experience of the community and of the fluorspar mining employees at St. Lawrence, Newfoundland.

Authors:  A J de Villiers; J P Windish; F de N Brent; B Hollywood; C Walsh; J W Fisher; W D Parsons
Journal:  Occup Health Rev       Date:  1971

7.  Potentiation of cigarette smoking and radiation: evidence from a sputum cytology survey among uranium miners and controls.

Authors:  P Band; M Feldstein; G Saccomanno; L Watson; G King
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

8.  Lung cancer mortality in uranium miners (methodological aspects).

Authors:  E Kunz; J Sevc; V Placek
Journal:  Health Phys       Date:  1978-10       Impact factor: 1.316

9.  Multistage models and primary prevention of cancer.

Authors:  N E Day; C C Brown
Journal:  J Natl Cancer Inst       Date:  1980-04       Impact factor: 13.506

10.  Statistical methods for censored survival data.

Authors:  N Breslow
Journal:  Environ Health Perspect       Date:  1979-10       Impact factor: 9.031

View more
  9 in total

1.  Healthy worker survivor bias in the Colorado Plateau uranium miners cohort.

Authors:  Alexander P Keil; David B Richardson; Melissa A Troester
Journal:  Am J Epidemiol       Date:  2015-04-01       Impact factor: 4.897

2.  Fitting general relative risk models for survival time and matched case-control analysis.

Authors:  Bryan Langholz; David B Richardson
Journal:  Am J Epidemiol       Date:  2009-12-31       Impact factor: 4.897

3.  Attributable mortality to radon exposure in Galicia, Spain. Is it necessary to act in the face of this health problem?

Authors:  Mónica Pérez-Ríos; Juan M Barros-Dios; Agustín Montes-Martínez; Alberto Ruano-Ravina
Journal:  BMC Public Health       Date:  2010-05-18       Impact factor: 3.295

4.  Residential radon appears to prevent lung cancer.

Authors:  Bobby R Scott
Journal:  Dose Response       Date:  2011-10-14       Impact factor: 2.658

5.  Lung Cancer and Radon: Pooled Analysis of Uranium Miners Hired in 1960 or Later.

Authors:  David B Richardson; Estelle Rage; Paul A Demers; Minh T Do; Nora Fenske; Veronika Deffner; Michaela Kreuzer; Jonathan Samet; Stephen J Bertke; Kaitlin Kelly-Reif; Mary K Schubauer-Berigan; Ladislav Tomasek; Lydia B Zablotska; Charles Wiggins; Dominique Laurier
Journal:  Environ Health Perspect       Date:  2022-05-23       Impact factor: 11.035

6.  What are the health costs of uranium mining? A case study of miners in Grants, New Mexico.

Authors:  Benjamin A Jones
Journal:  Int J Occup Environ Health       Date:  2014-10

Review 7.  Radon Exposure-Therapeutic Effect and Cancer Risk.

Authors:  Andreas Maier; Julia Wiedemann; Felicitas Rapp; Franziska Papenfuß; Franz Rödel; Stephanie Hehlgans; Udo S Gaipl; Gerhard Kraft; Claudia Fournier; Benjamin Frey
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

8.  Synergistic and Non-synergistic Associations for Cigarette Smoking and Non-tobacco Risk Factors for Cardiovascular Disease Incidence in the Atherosclerosis Risk In Communities (ARIC) Study.

Authors:  Jay H Lubin; David Couper; Pamela L Lutsey; Hiroshi Yatsuya
Journal:  Nicotine Tob Res       Date:  2017-07-01       Impact factor: 4.244

9.  Mortality of a cohort of French uranium miners exposed to relatively low radon concentrations.

Authors:  M Tirmarche; A Raphalen; F Allin; J Chameaud; P Bredon
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.